Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
Displaying: 342,868 trials in your specialties ()
View trials across your selected specialties

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

  • Status
    Completed
  • Phase
    Phase 1
  • Condition
    Vaccine, Influenza
View Full Trial
INTERVENTION

Biological: cH8/1N1 LAIV, Biological: cH5/1N1 IIV + adjuvant, Biological: cH5/1N1 IIV, Biological: cH8/1N1 IIV + adjuvant, Biological: Normal saline, Biological: Phosphate buffered saline

Eligibility
  • Ages: 18 to 39 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Duke University, Durham, North Carolina, United States

Brief Summary

The clinical study will evaluate safety and the immune response of a prime- boost regimen with a live attenuated influenza vaccine (LAIV) prime and an inactivated split influenza vaccine (IIV) boost with or without adjuvant.

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    B-cell Non Hodgkin Lymphoma, CLL
View Full Trial
INTERVENTION

Drug: TGR-1202, Drug: Pembrolizumab

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of Chicago, Chicago, Illinois, United States

Brief Summary

This study will be a standard 3+3 design with a lead in of TGR-1202 at dose of 600mg (dose level 1) or 800mg daily (dose level 2) for 6 weeks, i.e. 2 cycles, followed by pembrolizumab at 200mg every 3 weeks for 8 cycles along with TGR-1202 for patients with relapsed/refractory B-cell NHL or CLL. If the dose of 600mg daily of TGR-1202 (dose level 1) is tolerated in the first cohort the dose will be increased to 800mg qd which is the only and final dose escalation. If TGR-1202 is not tolerated at 600mg daily the dose will be decreased to 400mg daily. The lead in of TGR-1202 was chosen to ensure clinical benefit and to minimize the occurrence of early overlapping toxicity with pembrolizumab as most toxicities were observed early on in the treatment with idelalisib, a related PI3K-inhibitor, and rituximab.

Brain Dopaminergic Signaling in Opioid Use Disorders

  • Status
    Recruiting
  • Phase
    Early Phase 1
  • Condition
    Normal Physiology, Opioid-Related Disorders
View Full Trial
INTERVENTION

Other: Placebo, Drug: Methylphenidate

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Brief Summary

Background: The chemical messenger dopamine carries signals between brain cells. It may affect addiction. Heavy use of pain medicines called opioids may decrease the amount of dopamine available to the brain. Researchers want to study if decreased dopamine decreases self-control and increases impulsiveness. Objective: To learn more about how opiate use disorder affects dopamine in the brain. Eligibility: Adults 18-65 years old who are moderate or severe opiate users Healthy volunteers the same age Design: Participants will first be screened under another protocol. They will: - Have a physical exam - Answer questions about their medical, psychiatric, and alcohol and drug use history - Take an MRI screening questionnaire - Give blood and urine samples - Have their breath tested for alcohol Participants will have up to 3 study visits. They will have 2-3 positron emission tomography (PET) scans. A radioactive chemical will be injected for the scans. Participants will lie on a bed that slides in and out of the donut-shaped scanner. A cap or plastic mask may be placed on the head. Vital signs will be taken before and after the PET scans. Participants will get capsules of placebo or the study drug. They will rate how they feel before, during and after. Participants will have their breath and urine tested each day. Participants will have magnetic resonance imaging (MRI) scans. They will lie on a table that slides into a cylinder in a strong magnetic field. They may do tasks on a computer screen while inside the scanner. Participants will have tests of memory, attention, and thinking. Participants will wear an activity monitor for one week....

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Peripheral Nerve Injuries
View Full Trial
INTERVENTION

Drug: Placebo, Drug: Tesamorelin 2 Milligrams (MG)

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Jamie Shores, Baltimore, Maryland, United States

Brief Summary

The aim of this clinical trial is to assess the efficacy of tesamorelin as a therapy for peripheral nerve injuries. The investigators hypothesize that treatment with tesamorelin will allow for faster and greater recovery of motor and sensory function following surgical repair of injured peripheral nerves. Patients with upper extremity nerve injuries will be randomly assigned to receive either the drug or a placebo (inactive drug). A number of tests for nerve regeneration, muscle function and sensation will be performed every month for a total of 12 months. Outcomes in the patients treated with tesamorelin will be compared to outcomes in patients who received the placebo to determine the effectiveness of tesamorelin as a therapy for nerve injuries.

Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma

  • Status
    Other
  • Phase
    Phase 1
  • Condition
    Asthma
View Full Trial
INTERVENTION

Biological: hMSCs

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of Miami Miller School of Medicine, Miami, Florida, United States

Brief Summary

A Phase 1 investigation will be performed to test the safety of two doses of bone marrow-derived MSCs (20,000,000 and 100,000,000) administered via peripheral intravenous infusion.

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic...
View Full Trial
INTERVENTION

Drug: pralsetinib (BLU-667)

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Mayo Clinic, Phoenix, Arizona, United States

Brief Summary

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid cancer, RET-altered NSCLC and other RET-altered solid tumors.

Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carci...
View Full Trial
INTERVENTION

Drug: Capecitabine, Drug: Carboplatin, Drug: Cisplatin, Drug: Etoposide, Other: Laboratory Biomarker Analysis, Drug: Temozolomide

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Mercy Cancer Center-Hot Springs, Hot Springs, Arkansas, United States

Brief Summary

This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Drugs used in chemotherapy, such as temozolomide, capecitabine, cisplatin, carboplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Certain types of neuroendocrine carcinomas may respond better to treatments other than the current standard treatment of cisplatin and etoposide. It is not yet known whether temozolomide and capecitabine may work better than cisplatin or carboplatin and etoposide in treating patients with this type of neuroendocrine carcinoma, called non-small cell neuroendocrine carcinoma.

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
View Full Trial
INTERVENTION

Drug: Tremelimumab, Drug: MEDI4736, Drug: MEDI4736 + Tremelimumab

Eligibility
  • Ages: 18 to 96 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Research Site, Baltimore, Maryland, United States

Brief Summary

The purpose of this study is to determine the efficacy and safety of investigational medical products (MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 + tremelimumab combination therapy) in the treatment of patients with recurrent or metastatic carcinoma of the head and neck who have progressed during or after treatment with a platinum containing regimen for recurrent/metastatic disease.

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Urinary Incontinence, Urinary Bladder, Overactive
View Full Trial
INTERVENTION

Biological: OnabotulinumtoxinA

Eligibility
  • Ages: 12 to 17 Years (Child)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Children's of Alabama, Birmingham, Alabama, United States

Brief Summary

This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to overactive bladder in pediatric patients between the ages of 12 to 17 years who have not been adequately managed with anticholinergics.

Narcotic vs. Non-narcotic Pain Study Protocol

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Carpal Tunnel
View Full Trial
INTERVENTION

Drug: Narcotic, Drug: non-narcotic

Eligibility
  • Ages: 18 to 90 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

The Philadelphia Hand Center, Philadelphia, Pennsylvania, United States

Brief Summary

The purposes of this noninferiority randomized clinical trial are to: 1. determine whether the most commonly used commonly used non-narcotic analgesic (ibuprofen 600 mg + acetaminophen 325 mg) provides pain relief that is not unacceptably worse than the most commonly prescribed narcotic containing analgesic (hydrocodone 5 mg. + acetaminophen 325 mg, equivalent to Norco 5/325) in patients undergoing carpal tunnel release. 2. Determine whether the following covariates affect pain level following surgery or medication usage: gender, country (US/Canada), pre-operative CTS symptoms, site, workers compensation status and employment status (employed/self-employed/unemployed-able to work/unemployed-unable to work)